Sofinnova Investments’s Apellis Pharmaceuticals APLS Stock Holding History

Sofinnova Investments’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-49,580	Closed	-$1.62M	–	72
2020 Q2	$1.62M	Hold	49,580	–	–	0.1%	65
2020 Q1	$1.33M	Hold	49,580	–	–	0.12%	58
2019 Q4	$1.52M	Hold	49,580	–	–	0.11%	53
2019 Q3	$1.19M	Hold	49,580	–	–	0.11%	68
2019 Q2	$1.26M	Hold	49,580	–	–	0.12%	66
2019 Q1	$967K	Hold	49,580	–	–	0.09%	63
2018 Q4	$654K	Sell	49,580 -500,000	-91%	-$7.67M	0.08%	59
2018 Q3	$9.77M	Sell	549,580 -66,222	-11%	-$1.22M	0.87%	21
2018 Q2	$13.5M	Sell	615,802 -295,950	-32%	-$6.8M	1.53%	15
2018 Q1	$20.2M	Buy	+911,752	New	+$17.9M	3.46%	10

Other funds holding APLS

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Sofinnova Investments's APLS Position: Q3 2020 in Review

Sofinnova Investments sold out of Apellis Pharmaceuticals (APLS) in Q3 2020, closing a stake of 49,580 shares — an estimated $1.62M sold.

Sofinnova Investments first reported a position in APLS in Q1 2018 and held it in 10 quarters. The position peaked at $20.2M in Q1 2018. 145 funds tracked by Wall St. Rank hold APLS as of Q3 2020.

Sofinnova Investments reported no remaining Apellis Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Sofinnova Investments sold 49,580 Apellis Pharmaceuticals shares in Q3 2020, an estimated $1.62M.
Sofinnova Investments first reported a position in Apellis Pharmaceuticals in Q1 2018 and held it in 10 quarters.
Sofinnova Investments's Apellis Pharmaceuticals position peaked at $20.2M in Q1 2018.
145 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2020.

Based on Sofinnova Investments's 13F filing for Q3 2020, filed 13 Nov 2020.